RU-2/1 Yugoslav Peoples Army VHF Radio Station #2298
RU-2/1 Yugoslav Peoples Army VHF Radio Station #2298
The RU-2/1 is a ex-Yugoslav Peoples Army VHF radio starion. The radio is a low power portable VHF (FM) Radio, made by RUDI CAJAVEC, from Banja Luka (Ex Yugoslavia). The RU-2/1 has been designed to provide command communications at battalion and company level. It was also used in vehicles and by mounted troops. The RU2/1 replaced the older RUP-12 ex-Yugoslav peoples army VHF radio.
Frequency Range 30 to 69.95 MHz in 50 Khz steps. The desired frequency is set by 3 knobs on the front plate of the radio.
The radio is powered by a standard JNA 12V/6aH battery pack. It can also be powered externally from 12V Vehicle power supply.
The RU-2/1 and accessories are supplied in very good condition, tested and operational. Please choose from accessories options below.
Technical Specification:
Frequency Range: 30 to 69.95 MHz
Channel Spacing: 50 KHz
Modes of Operation: FM
Power Requirements: 12 VDC
Battery: 12 Volt
Epidermal growth factor receptor mutations: gefitinib and erlotinib treatment of non-small cell lung cancer research targets
Gefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) class of drugs, is currently the treatment of non-small cell lung cancer (NSCLC) hot spots, has been confirmed in several clinical trials, East Asians, women, no history of smoking and effective in patients with adenocarcinoma, further research reveals cancer patients with EGFR tyrosine kinase domain mutations on EGFR-TKI sensitivity are closely related. These mutations include frame deletions, point mutations and other types. This article reviews the EGFR mutation status and progress.
Epidermal growth factor receptor mutations: gefitinib and erlotinib treatment of non-small cell lung cancer research targets
ReplyDeleteGefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) class of drugs, is currently the treatment of non-small cell lung cancer (NSCLC) hot spots, has been confirmed in several clinical trials, East Asians, women, no history of smoking and effective in patients with adenocarcinoma, further research reveals cancer patients with EGFR tyrosine kinase domain mutations on EGFR-TKI sensitivity are closely related. These mutations include frame deletions, point mutations and other types. This article reviews the EGFR mutation status and progress.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Enzalutamide
TOK-001
Anastrozole
GSK1292263
TAK-875
Andarine
Maraviroc
Dolutegravir
Elvitegravir
HIV-1 integrase inhibitor 2